Feed - Buzzberg

21:00
Jun 03 ◎

VEEV FY2027 Q1 Watch

Veeva Systems Inc. Class A (VEEV) FY2027 Q1 Earnings Call

VEEV CRM ICLR ▾

Peter Gassner

Management's tone is confident, with strong quarterly results and continued investment in new AI-led growth vectors like Falcon, despite unchanged macro guidance.

"We had a strong start to the year, delivering results ahead of our guidance."

VEEV WATCH

Paul Schala

Veeva's commercial cross-sell is succeeding: it has 10 of 16 top-20 CRM migration wins, with win rates above 80%, and close to 40 successful migrations. — This is direct, quantifiable share gain against Salesforce in the most valuable pharmaceutical CRM accounts, signaling continued erosion of Salesforce's Life Sciences footprint.

"The remaining four, um, there's 10, 10 wins for Viva so far, six for Salesforce."

CRM WATCH

Peter Gassner

The first Falcon agent deployments are focused on high-volume, outsourced labor roles — clinical trial document intake and safety case triage — the same type of work that specialized labor providers and CROs do today. — While CROs should benefit from pharma running more trials, specialized back-office labor providers that monetize per-case document processing face an existential threat as Veeva's agents take over that work cheaper and faster.

"the first ones we're looking at are processing documentation involved with clinical trials, specifically the stuff that comes from clinical sites."

ICLR WATCH

HIGH

22:00
Mar 04 ◎

VEEV FY2026 Q4 Watch

Veeva Systems Inc. Class A (VEEV) FY2026 Q4 Earnings Call

IQV OPENAI ANTHROPIC CRM ▾

Peter Gassner

Veeva is taking market share from IQVIA in the CRM space for top-20 pharma accounts.

"a couple of the large top 20s, for example, were on IQVIA. Okay, those are going on over to Viva."

IQV WATCH

Peter Gassner

Veeva's focus on agentic AI and data integration with AI doctors/large language models could help address a key 90% value loss in life sciences, potentially expanding the pharma market. — If Veeva successfully connects its software to AI-driven patient care, it could help improve patient outcomes and increase the total addressable market for its customers.

"AI doctors and large-angles models can help bridge that gap between doctors and patients. So maybe that 90% inefficiency goes down to 50%."

OPENAI WATCH ANTHROPIC WATCH

Peter Gassner

Veeva is accelerating the end-of-support date for its legacy CRM product by 9 months to December 2029, signaling faster-than-expected industry migration and stronger Vault CRM traction. — A faster end-of-support deadline will force more Salesforce CRM users to make migration decisions sooner, potentially accelerating Veeva's market share gains and impacting Salesforce's remaining pharma CRM revenue.

"I know of one top 20 that has... a large number of development team contracted in India from a third-party system integrator. They're coding basically a custom solution."

CRM WATCH

HIGH

22:00
Nov 20 ◎

VEEV FY2026 Q3 Watch

Veeva Systems Inc. Class A (VEEV) FY2026 Q3 Earnings Call

MSFT MRK CRM RNR IQV ▾

Peter Gassner

Veeva's AI roadmap includes agents in all application areas by end of 2026, with a focus on replacing labor in processes like ETMF intake. — This illustrates the broader trend of AI-driven automation in clinical workflows, which could impact staffing and operational efficiency for pharma companies.

"They want to use Microsoft where Microsoft can help them."

MSFT WATCH

Peter Gassner

Merck is a strategic R&D customer, but the partnership is not a full-platform commitment, indicating potential for further expansion or limited scope.

"As it relates to Merck, there was a strategic partnership we announced. There was not really that they would use Viva everywhere, but a strategic partnership that we announced."

MRK WATCH

Paul Shawa

Veeva says customers are beginning to see 'compounding' value from cross-X as digital marketing spend grows, particularly with new digital channels. — This suggests increased demand for ad-tech and analytics platforms that can measure digital pharma marketing, benefiting Google's ad network and potentially pressuring traditional media.

"They have a very new product in the CRM space. They don't have everything that we've talked about, all of the other software products, commercial content, across X business, all of the data assets"

CRM WATCH

Peter Gassner

Veeva's new LIMS (laboratory information management) product aims to disrupt a market dominated by legacy, on-premise solutions, with a greenfield opportunity as new manufacturing plants are built. — This could signal a long-term shift in lab software spending, impacting legacy providers and potentially benefiting Veeva's growth.

"there's two main solutions used out in that area, and they're both on-premise hosted solutions that are not modern, critically important, but not modern."

RNR WATCH ILL WATCH

Peter Gassner

Veeva expects Crossix to potentially match the size of the entire CRM suite by 2030, signaling significant growth in digital marketing measurement. — This implies that the shift to digital marketing measurement is accelerating at the expense of traditional CRM spend, impacting both IQVIA and Salesforce.

"It's certainly giving Viva a spring in our step, this partnership with IQVIA"

IQV WATCH

Peter Gassner

"So there's really a compounding effect of the excellence that we're developing in Cross-X."

GOOGL WATCH

Peter Gassner

Veeva is entering the 'age of AI' for CRM and expects 'probabilistic computing' to change what a CRM system can do, suggesting a significant product transition ahead. — This indicates that Veeva is pivoting its commercial suite towards AI-driven agents and insights, potentially reshaping competitive dynamics in the software space.

"Now we are entering the age of AI, probabilistic computing, to really drive and change what a CRM system can do."

SHOP WATCH

Brian Van Wagner

Guidance was raised for the full year due to strong execution and earlier-than-expected deal closures, signaling continued momentum.

"we had some earlier timing of deal closure than we expected that contributed to some of the outperformance in the quarter and the raise in Q4 and therefore for the full year."

VEEV WATCH

HIGH

Feed — Buzzberg